Inhibition of abcb1 expression overcomes acquired docetaxel resistance in prostate cancer

Molecular Cancer Therapeutics

Volumn 12, Issue 9, 2013, Pages 1829-1836

  Zhu, Yezi ^a,b   Liu, Chengfei ^a   Nadiminty, Nagalakshmi ^a   Lou, Wei ^a   Tummala, Ramakumar ^a   Evans, Christopher P ^a,c   Gao, Allen C ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; APIGENIN; DOCETAXEL; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; RECEPTOR UPREGULATION;

ANTINEOPLASTIC AGENTS; APIGENIN; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84884521969     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0208     Document Type: Article

References (33)

1. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6:76-85.
2. Kim SJ, Kim SI. Current treatment strategies for castration-resistant prostate cancer. Korean J Urol 2011;52:157-65.
3. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
4. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007;446:749-57.
5. Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011;14:192-205.
6. Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2007;2:920-42.
7. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8: 12-23.
8. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda Y, Shigeno K, et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 2006;12:6116-24.
9. Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, et al. Induction of clusterin by AKT-Role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther 2010;9:1831-41.
10. Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. J Urol 2011;185: 2376-81.
11. O'Neill AJ, Pencipe M, Dowling C, Fan Y, Mulrane L, Gallagher W, et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 2011;10:126.
12. Gottesman MM, Fojo T, Bates S. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
13. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, et al. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 2013;73:418-27.
14. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notchand hedgehog-dependent tumor-initiating cells. Cancer Cell 2012;22: 373-88.
15. Shukla S, Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clin Cancer Res 2004;10:3169-78.
16. Marin-Aguilera M, Codony-Servat J, Kalko SG, Fernandez PL, Bermudo R, Buxo E, et al. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 2012;11: 329-39.
17. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105-27.
18. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5:219-34.
19. Sanchez C, Mercado A, Contreras HR, Mendoza P, Cabezas J, Acevedo C, et al. Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins. Prostate 2011;71:1810-7.
20. Bhangal G, Halford S, Wang J, Roylance R, Shah R, Waxman J. Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 2000;5:118-21.
21. Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 2001;287:914-20.
22. Shukla S, Gupta S. Apigenin: a promising molecule for cancer prevention. Pharm Res 2010;27:962-78.
23. Gupta S, Afaq F, Mukhtar H. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 2002;21: 3727-38.
24. Shukla S, Gupta S. Molecular mechanisms for apigenin-induced cellcycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog 2004;39:114-26.
25. Iwashita K, Kobori M, Yamaki K, Tsushida T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci Biotechnol Biochem 2000;64:1813-20.
26. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 2000;87:595-600.
27. Way TD, Kao MC, Lin JK. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 2004;279:4479-89.
28. Long X, Fan M, Bigsby RM, Nephew KP. Apigenin inhibits antiestrogen- resistant breast cancer cell growth through estrogen receptoralpha- dependent and estrogen receptor-alpha-independent mechanisms. Mol Cancer Ther 2008;7:2096-108.
29. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 1999;35:1517-25.
30. Li ZD, Liu LZ, Shi X, Fang J, Jiang BH. Benzo[a]pyrene-3,6-dione inhibited VEGF expression through inducing HIF-1alpha degradation. Biochem Biophys Res Commun 2007;357:517-23.
31. Wang W, Heideman L, Chung CS, Pelling JC, Koehler KJ, Birt DF. Cellcycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinog 2000;28:102-10.
32. Yin F, Giuliano AE, Law RE, Van Herle AJ. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 2001;21:413-20.
33. Xu Y, Xin Y, Diao Y, Lu C, Fu J, Luo L, et al. Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. PLoS ONE 2011;6:e29169.